SMAD pathway mediation of BDNF and TGF beta 2 regulation of proliferation and differentiation of hippocampal granule neurons.
Hippocampal granule cells self-renew throughout life, whereas their cerebellar counterparts become post-mitotic during early postnatal development, suggesting that locally acting, tissue-specific factors may regulate the proliferative potential of each cell type. Confirming this, we show that conditioned medium from hippocampal cells (CM(Hippocampus)) stimulates proliferation in cerebellar cultures and, vice versa, that mitosis in hippocampal cells is inhibited by CM(Cerebellum). The anti-proliferative effects of CM(Cerebellum) were accompanied by increased expression of the cyclin-dependent kinase inhibitors p21 and p27, as well as markers of neuronal maturity/differentiation. CM(Cerebellum) was found to contain peptide-like factors with distinct anti-proliferative/differentiating and neuroprotective activities with differing chromatographic properties. Preadsorption of CM(Cerebellum) with antisera against candidate cytokines showed that TGFbeta2 and BDNF could account for the major part of the anti-proliferative and pro-differentiating activities, an interpretation strengthened by studies involving treatment with purified TGFbeta2 and BDNF. Interference with signaling pathways downstream of TGFbeta and BDNF using dominant-negative forms of their respective receptors (TGFbeta2-RII and TRKB) or of dominant-negative forms of SMAD3 and co-SMAD4 negated the anti-proliferative/differentiating actions of CM(Cerebellum). Treatment with CM(Cerebellum) caused nuclear translocation of SMAD2 and SMAD4, and also transactivated a TGFbeta2-responsive gene. BDNF actions were shown to depend on activation of ERK1/2 and to converge on the SMAD signaling cascade, possibly after stimulation of TGFbeta2 synthesis/secretion. In conclusion, our results show that the regulation of hippocampal cell fate in vitro is regulated through an interplay between the actions of BDNF and TGFbeta.
Lu
Jie
J
NeuroAdaptations Group, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, D-80804 Munich, Germany.
Wu
Yan
Y
Sousa
Nuno
N
Almeida
Osborne F X
OF
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism* / Q000502:physiology; D002453:Cell Cycle / Q000502:physiology; D002454:Cell Differentiation / Q000502:physiology*; D049109:Cell Proliferation; D002531:Cerebellum / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000502:physiology*; D006624:Hippocampus / Q000166:cytology / Q000378:metabolism*; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009474:Neurons / Q000166:cytology* / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases; D051381:Rats; D017208:Rats, Wistar; D000077294:Receptor, Transforming Growth Factor-beta Type II; D020813:Receptor, trkB / Q000378:metabolism; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism / Q000502:physiology*; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology; D051785:Smad Proteins; D015534:Trans-Activators / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000378:metabolism* / Q000502:physiology; D053781:Transforming Growth Factor beta2
D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor; D004268:DNA-Binding Proteins; D018125:Receptors, Transforming Growth Factor beta; D051785:Smad Proteins; D015534:Trans-Activators; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2; D020813:Receptor, trkB; D017346:Protein Serine-Threonine Kinases; D020928:Mitogen-Activated Protein Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II